You are here

Director/PDMR Shareholding

Director/PDMR Shareholding

20 December, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)

Notification of transactions by persons discharging managerial responsibilities

1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameSusan Kilsby
2.Reason for the notification
a)Position / statusChairman – PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAcquisition of ADSs, being the part of Ms. Kilsby’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.0470164
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionXNAS / XBOS / ARCX


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameOlivier Bohuon
2.Reason for the notification
a)Position / statusSenior Independent Director - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)
 
 
Identification codeISIN: JE00B2QKY057
b)Nature of the transactionAcquisition of Ordinary Shares, being the part of Mr. Bohuon’s total fees that are paid in Ordinary Shares for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
£44.31140
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionLSE (TRQX)


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameIan Clark
2.Reason for the notification
a)Position / statusNon-Executive Director - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAcquisition of ADSs, being the part of Mr. Clark’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.047044
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionXNAS / XBOS / ARCX


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameGail Fosler
2.Reason for the notification
a)Position / statusNon-Executive Director - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAcquisition of ADSs, being the part of Ms. Fosler’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.047047
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionXNAS / XBOS / ARCX


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameSteven Gillis
2.Reason for the notification
a)Position / statusNon-Executive Director - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAcquisition of ADSs, being the part of Dr. Gillis’ total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.047049
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionXNAS / XBOS / ARCX


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameDavid Ginsburg
2.Reason for the notification
a)Position / statusNon-Executive Director - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAcquisition of ADSs, being the part of Dr. Ginsburg’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.047044
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionXNAS / XBOS / ARCX


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameSara Mathew
2.Reason for the notification
a)Position / statusNon-Executive Director - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAcquisition of ADSs, being the part of Ms. Mathew’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.047046
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionXNAS / XBOS / ARCX


1.Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”)
a)NameAlbert Stroucken
2.Reason for the notification
a)Position / statusNon-Executive Director - PDMR
b)Initial notification / amendmentInitial notification
3.Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
b)LEI54930005LQRLI2UXRQ59
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentShire plc American Depositary Shares (“ADSs”)
 
 
Identification codeISIN: US82481R1068
b)Nature of the transactionAcquisition of ADSs, being the part of Mr. Stroucken’s total fees that are paid in ADSs for the period of service from October 1 to December 31, 2018.
c)Price(s) and volume(s)Price(s)Volume(s)
$168.047063
d)Aggregated information

- Aggregated volume - Price
N/A (single transaction)
 
 
 
e)Date of the transactionDecember 19, 2018
f)Place of the transactionXNAS / XBOS / ARCX

Sarah Rixon
Senior Company Secretarial Assistant

For further information please contact:

Investor Relations  
Christoph Brackmannchristoph.brackmann@shire.com+41 41 288 41 29
Sun Kimsun.kim@shire.com+1 617 588 8175
Scott Burrowsscott.burrows@shire.com+41 41 288 4195
   
Media  
Katie Joycekjoyce@shire.com +1 781 482 2779
   

NOTES TO EDITORS

About Shire

Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions. We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what’s next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.
 
Championing patients is our call to action - it brings the opportunity - and responsibility - to change people’s lives.

www.shire.com

Thursday, December 20, 2018 - 08:00